Gland Pharma

Breakout stocks: Nifty Pharma, Biocon, Cipla break over 200-DMA; what next?

The Nifty Pharma index and select shares such as Biocon, Cipla, Zydus Life and Gland Pharma were trading above the respective 200-DMAs after more than 2 months; show technical charts.

Gland Pharma share rises 2% in trade on Wednesday, June 4; here's why

Gland Pharma shares rose after it secured United States Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection 2.5 mg/mL.

Gland Pharma stock volatile after announcing Q4 results, dividend; Details

Gland Pharma shares volatile after posting Q4 results and dividend; check more details

Gland Pharma gets USFDA nod for Vyzulta generic with 180-day exclusivity

Gland Pharma on Wednesday said it has received approval from the US health regulator for a generic medication to treat conditions related to high pressure in the eye. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Latanoprostene Bunod Ophthalmic Solution, (0.024 per cent), the drug firm said in a statement. The company's product is bioequivalent and therapeutically equivalent to Bausch and Lomb, Inc's Vyzulta ophthalmic solution, it added. The product is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The company is the exclusive first-to-file and is eligible for 180 days of generic drug exclusivity, Gland Pharma said. According to IQVIA, the product had sales of around USD 171 million in the US for the 12 months ending February 2025. Shares of Gland Pharma on Wednesday ended 1.04 per cent down at Rs 1,398.35 apiece on the BSE.

Mutual Funds increased stake in 14 pharma stocks in Q4FY25; do you own any?

Analysts believe that pharma shares continue to see buying interest, given the inelastic demand for medicines; tariffs, if any could have minimal impact on the industry.

These 3 pharma stocks have surged over 50% in April; check full list here

A total of 11 pharma and healthcare-related stocks have rallied more than 20% thus far in April on hopes of a likely softer tariff-related stance by the US President Donald Trump.

5 pharma stocks that you should stay away from given their tech charts

Technical charts hint that pharma shares such as Cipla, Lupin, Sun Pharma, Zydus Lifesciences and Gland Pharma could slide up to 23% as Trump tariff threat on pharma import looms.

Gland Pharma jumps 6% on multiple bulk deals; check buyers' detail here

According to NSE bulk deal data, Vanguard Emerging Markets Stock Index Fund A Series of VIEIF purchased 0.83 million shares

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Gland Pharma shares slip 5% on disappointing revenue growth in Q3

Analysts at InCred Equities said they are disappointed with the repeated delay in Cenexi's turnaround and will reassess the situation constructively once the facility is back on track

Gland Pharma Q3 result: Net profit rises 7% to Rs 205 cr as expenses drop

Rivals Sun Pharma and Cipla beat third-quarter profit estimates, while Dr Reddy's missed expectations. All three drugmakers saw muted growth in the North American market, including the US

USFDA issues Establishment Inspection Report to Gland Pharma; stock up 3%

The pharmaceutical company's shares were quoted at an all-time high of Rs 4,350 on August 21, 2021, while they touched their all-time low of Rs 861.50 on May 22, 2023

Stocks to Watch, Dec 26: IOC, Gland Pharma, BPCL, Ramky Infra, Ceigall

Stocks to watch on December 26, 2024: Indian Oil Corporation plans to sign an agreement with the Odisha government in January for a Naphtha Cracker Project at Paradip

Gland Pharma jumps 5% after USFDA nod for Vitamin-K deficiency drug

Shares of Gland Pharma surged up to 4.76 per cent at Rs 1860 on the BSE in the early morning trade of Thursday

Stocks to Watch, Dec 12: Jubilant FoodWorks, SBI, Vedanta, Swiggy, Emami

Stocks to Watch, Dec 12: From Swiggy to Jubilant Foodworks, here are some stocks that will be on investors radar today

Here's why Gland Pharma share was up 3% on December 3; details here

The uptick in Gland Pharma share came after the company said that it has received approval from the United States Food and Drug Administration (US FDA) for Latanoprost Ophthalmic Solution

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Upper-teens EPS growth likely for Gland Pharma in next two financial years

Analysts are downgrading optimistic EPS estimates for FY25 and FY26, due to continuing slowdown in US sales and a temporary issue at Cenexi's site in Belgium

Gland Pharma soars 13% on better than expected Q2 performance

Despite increased EBITDA loss at Cenexi, the overall consolidated EBITDA margin was better-than-expected at 21.1%, led by better segmental mix and controlled operational cost for the quarter.

Gland Pharma Q2FY25 results: Net profit falls 15.7% to Rs 164 crore

The company reported consolidated net profit of Rs 164 crore ($19.5 million) for the quarter ended Sept. 30, a 15.7 per cent decrease from the year-ago period